NUWE
NASDAQNuwellis Inc.
SectorHealth CareIndustryBiotechnology: Electromedical & Electrotherapeutic Apparatus
Price$2.03+0.00 (+0.25%)
04:30 PM07:45 PM
News · 26 weeks67-67%
2026-01-252026-07-19
Mix3590d
- Other12(34%)
- SEC Filings12(34%)
- Insider5(14%)
- Earnings2(6%)
- Offering2(6%)
- Leadership2(6%)
Latest news
25 items- SECNuwellis Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Nuwellis, Inc. (0001506492) (Filer)
- PRNuwellis Awarded U.S. Patent for Novel Catheter Technology Designed to Enhance Extracorporeal TherapiesMINNEAPOLIS, July 16, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,678,592, covering the company’s Dual Lumen Catheter, a novel peripheral dual-lumen catheter designed for use with extracorporeal therapies, including ultrafiltration, dialysis, and continuous renal replacement therapy (CRRT) modalities. The patent was issued on July 14, 2026. It further expands Nuwellis' intellectual property portfolio and supports the Company's broader strategy of advancing differentiated technologies acr
- SECSEC Form DEF 14A filed by Nuwellis Inc.DEF 14A - Nuwellis, Inc. (0001506492) (Filer)
- PRNuwellis to Showcase Aquadex Therapy at KidneyBee Summit 2026MINNEAPOLIS, July 07, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces its participation in the KidneyBee Summit 2026, taking place July 14-16, 2026, at Children's Hospital Colorado in Aurora, Colorado. As part of its participation, Nuwellis will engage with conference attendees to discuss the role of precise fluid management in pediatric patients with acute kidney injury, cardiorenal conditions, and fluid overload. The Company will highlight the Aquadex SmartFlow® System, which enables controlled, predictable fluid removal and is increasingly being utilized at leading p
- INSIDERSEC Form 3 filed by new insider Mccormick Michael Kendrick3 - Nuwellis, Inc. (0001506492) (Issuer)
- SECSEC Form PRE 14A filed by Nuwellis Inc.PRE 14A - Nuwellis, Inc. (0001506492) (Filer)
- PRNuwellis Celebrates Five Years of Support of the Pediatric Cardiac Critical Care Consortium (PC⁴)MINNEAPOLIS, June 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces the five-year anniversary of its support of the annual conference for the Pediatric Cardiac Critical Care Consortium (PC4), an alliance aiming to improve the quality of care to patients with critical pediatric and congenital cardiovascular disease. Over the past five years, Nuwellis has collaborated with leading pediatric cardiac critical care institutions to support clinician education, scientific exchange, and awareness of fluid management strategies in critically ill children. Through these efforts
- PRNuwellis Announces Pediatric Expansion in Michigan with First Aquadex SmartFlow® InstallationsMINNEAPOLIS, June 25, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces its expansion in Michigan with the installation of three Aquadex SmartFlow® systems at a leading pediatric healthcare provider. This represents Nuwellis’ first pediatric program in the state of Michigan and further expands the Company’s growing presence in pediatric critical care into a significant healthcare market. "Adding our first pediatric program in Michigan advances our strategy to expand Aquadex adoption in pediatric care," said Nuwellis’ Incoming CEO Mike McCormick. "Leading pediatric center
- PRIncoming Nuwellis CEO Mike McCormick Underscores Strategic Priorities for Continued Market Expansion in Pediatric Category and Revenue Generation in Letter to ShareholdersMINNEAPOLIS, June 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, reviews the year-to-date and outlines strategic priorities in a Letter to Shareholders from newly appointed CEO, Mike McCormick. Dear Valued Shareholders, Recently we announced an important leadership transition for Nuwellis. Effective June 30, 2026, I will assume the role of Chief Executive Officer, while John Erb will transition from his executive responsibilities and continue as Chairman of the Board. We embark on this leadership transition with growing commercial momentum, improving margins, and a streng
- PRNuwellis Expands Critical Care Education with Aquadex Training at University of Minnesota Critical Care Cardiology Education SummitMINNEAPOLIS, June 18, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, highlighted the clinical utility of its Aquadex SmartFlow® system at the 4th annual Critical Care Cardiology Education Summit (CCCES), hosted by the University of Minnesota. As part of the conference's skills-based curriculum, conference instructors conducted focused Aquadex training sessions that provided participants with practical experience using the Company's ultrafiltration technology. More than 280 physicians completed hands-on Aquadex training during the event, representing one of the largest concentrat
- PRNuwellis Appoints Mike McCormick as Chief Executive OfficerMINNEAPOLIS, June 16, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces the appointment of Mike McCormick as Chief Executive Officer, effective June 30, 2026. John Erb, who currently serves as President, CEO, and Chairman of the Board, will transition from his executive leadership role and continue serving as Chairman of the Board. "Mike brings an exceptional combination of operational leadership, commercial expertise, and strategic vision," said Erb. "His deep understanding of the medical device industry and proven track record of building and scaling innovative healthc
- SECNuwellis Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Nuwellis, Inc. (0001506492) (Filer)
- PRNuwellis Expands Collaboration with Major South Carolina Healthcare System to Install New Aquadex SmartFlow® Devices at One of its Children's HospitalsMINNEAPOLIS, June 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announces an expanded collaboration with a major South Carolina healthcare system to integrate Aquadex SmartFlow® devices into the clinical care programs at one of its children's hospitals. The provider has also upgraded to the latest Aquadex devices at its two locations that already use the technology, helping clinicians provide controlled, predictable fluid removal for pediatric patients. "Expanding this important collaboration will bring our Aquadex therapy to more pediatric patients in need," said Nu
- PRNuwellis Announces Closing of $6.0 Million Registered Public OfferingMINNEAPOLIS , June 08, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announces the closing of a public offering of 1,903,338 shares of its common stock ("Common Stock"), pre-funded warrants to purchase 18,096,662 shares of Common Stock, in each case with accompanying Series C Warrants to purchase up to 60,000,000 shares of Common Stock and Series D Warrants to purchase up to 20,000,000 shares of Common Stock with gross proceeds of approximately $6.0 million. The public offering price per share of Common Stock and accompanying warrants is $0.30 per share and accompanying
- SECSEC Form 424B4 filed by Nuwellis Inc.424B4 - Nuwellis, Inc. (0001506492) (Filer)
- PRNuwellis Announces Pricing of $6 Million Public OfferingMINNEAPOLIS, June 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announces the pricing of a public offering of 20,000,000 shares of its common stock ("Common Stock") (or pre-funded warrants in lieu thereof) with accompanying warrants to purchase common stock for gross proceeds of approximately $6 million (the "Offering"). The public offering price per share of Common Stock and accompanying warrants is $0.30 per share and accompanying warrants. Each of the Series C Warrants and Series D Warrants has an exercise price of $0.30 and will be exercisable for a period of fi
- SECSEC Form S-1MEF filed by Nuwellis Inc.S-1MEF - Nuwellis, Inc. (0001506492) (Filer)
- SECSEC Form EFFECT filed by Nuwellis Inc.EFFECT - Nuwellis, Inc. (0001506492) (Filer)
- SECAmendment: SEC Form S-1/A filed by Nuwellis Inc.S-1/A - Nuwellis, Inc. (0001506492) (Filer)
- SECSEC Form FWP filed by Nuwellis Inc.FWP - Nuwellis, Inc. (0001506492) (Subject)
- SECAmendment: SEC Form S-1/A filed by Nuwellis Inc.S-1/A - Nuwellis, Inc. (0001506492) (Filer)
- SECSEC Form SD filed by Nuwellis Inc.SD - Nuwellis, Inc. (0001506492) (Filer)
- SECSEC Form S-1 filed by Nuwellis Inc.S-1 - Nuwellis, Inc. (0001506492) (Filer)
- SECSEC Form 10-Q filed by Nuwellis Inc.10-Q - Nuwellis, Inc. (0001506492) (Filer)
- PRNuwellis Announces Successful Completion of FDA Pre-Submission 510(k) Meeting to Expand Aquadex LabelMINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announces the successful completion of a recent pre-submission meeting with the U.S. Food and Drug Administration (FDA) regarding the proposed label expansion of the Aquadex SmartFlow® System to support pediatric patients weighing 5 kg and above. The currently cleared indication is for patients weighing 20 kg and above. "In low-weight pediatric patients, fluid management is highly sensitive and requires careful clinical oversight," said Nuwellis' Director of Clinical Strategy Stuart Goldstein, M.D. "The a
NUWE FAQ
6 questionsWhat does Nuwellis Inc. do?
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria...Where does NUWE stock trade?
Nuwellis Inc. (NUWE) is listed on NASDAQ.What sector and industry is NUWE in?
Nuwellis Inc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.What are analysts saying about NUWE?
Nuwellis Inc. has had 1 recent analyst action on file. The most recent action was from ROTH MKM: Buy with a $1700.00 price target on 2024-07-29. Recent price targets cluster around $1700.00.What companies are similar to NUWE?
Notable peers in the same industry include MDT (Medtronic plc.), MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation). Compare NUWE side-by-side with any of them on Quantisnow.How can I track NUWE on Quantisnow?
Quantisnow aggregates Nuwellis Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NUWE to receive live email and push alerts on every new disclosure.